Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit

Trial Profile

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2018

At a glance

  • Drugs Amfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Tris Pharma
  • Most Recent Events

    • 12 Nov 2018 Results presented in the Tris Pharma media release.
    • 12 Nov 2018 According to a Tris Pharma media release, data from this trial was presented at the 2018 Neuroscience Education Institute (NEI) Congress.
    • 19 Oct 2017 Planned End Date changed from 30 Sep 2017 to 30 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top